













































Pharmaceuticals – Pipeline Overview¹ (as of Dec 13, 2022)

Phase 0 ²	Phase I	Phase II	Phase III
DGKalpha Inh (BAY 2862789)  ●	Elimusertib (ATR Inhibitor) (BAY 1895344)  ●	Regorafenib (combi Nivolumab) (BAY 734506)  ○ # Solid tumors (recurrent or metastatic)	Copanlisib (PI3K Inhibitor) (BAY 806946)  ○ # Non-Hodgkin Lymphoma (CHRONOS-4)
PSMA TAC (BAY 3546828)  ●	AhR Inhibitor (BAY 2416964)  ●	Asundexian (FXIa Inhibitor) (BAY 2433334)  ● /// 2° Stroke Prevention (PACIFIC-STROKE) /// Major Adverse Cardiac Events Prevention (PACIFIC-AMI)	Darolutamide (AR Inhibitor) (BAY 1841788)  ○ # Prostate Cancer (mHSPC) (ARANOTE) # Adjuvant Prostate Cancer (DASL-HiCaP)
PSMA SMOL TAC (BAY 3563254)  ●	mEGFR Inhibitor (BAY 2927088)  ●	Runcaciguat (sGC Activator) (BAY 1101042)  ● # Chronic Kidney Disease (CKD) (CONCORD) # Non-prolif. Diabetic Retinopathy (NPDR) (NEON-NPDR)	Finerenone (MR Antagonist) (BAY 948862)  ○ # Heart Failure (HFmr/pEF) (FINEARTS-HF) # Non-diabetic CKD (FIND-CKD)
VVD NRF2 Inh (BAY 3605349)  ●	227Th-Trastuzumab corixetan (HER2 TTC) (BAY 2701439)  ●	BDKRB1 Receptor Antagonist (BAY 2395840)  ● # Neuropathic Pain (BRADINP)	Vericiguat (sGC Stimulator) (BAY1021189)  ○ # Heart Failure (HFREF) (VICTOR ³)
VVD STAT3 Inh (BAY 3630914)  ●	DGKzeta Inhibitor (BAY 2965501)  ●	Gadoquatrane (High Relaxivity Contrast Agent) (BAY 1747846)  ● # Magnetic Resonance Imaging (HRCA-PAT)	Asundexian (FXIa Inhibitor) (BAY 2433334)  ● # Stroke Prevention in Atrial Fibrillation (OCEANIC-AF)
SEMA 3^a (BAY 3401016)  ●	CCR8 Ab (BAY 3375968)  ●	Adrenomedullin Pegol (PEG-ADM) (BAY 1097761)  ● # Acute Resp. Distress Syn. (ARDS) (SEAL)	Elinzanetant (Neurokinin-1,3 Rec Antagonist) (BAY 3427080)  ● # Vasomotor Symptoms (OASIS)
LGMD2i Gene Therapy (LION-101)  ●	Congestive Heart Failure Gene Therapy (NAN-101)  ●		Aflibercept 8MG (BAY 865321)  ○ # Diabetic Macular Edema (DME) (PHOTON ⁴) # Neovasc. Age-rel. Macular Degen. (nAMD) (PULSAR)
Next Generation Liver MRI (BAY 3393081)  ●	sGC Activator (BAY 3283142)  ●		
	Anti-a2AP (BAY 3018250)  ●		
	P2X4 Antagonist (BAY 2328065)  ●		
	BDKRB1 Receptor Antagonist (BAY 2395840)  ●		
	Zabedoseritib (IRAK4 Inhibitor) (BAY 1834845)  ●		
	sGC Activator (BAY 1211163)  ●		
	Parkinson's Disease Cell Therapy (BRT-DA-01)  ●		
	Parkinson's Disease Gene Therapy (AAV2-GDNF-PD)  ●		
	Multiple System Atrophy Gene Therapy (AAV2-GDNF-MSA)  ●		
	Pompe Disease Gene Therapy (ACTUS-101)  ●		
	Huntington's Disease Gene Therapy (BV-101)  ●		

Submissions
Darolutamide (AR Inhibitor) / ADT with Chemotherapy  ○ # EU, Japan, China: mHSPC
Aflibercept (VEGF inhibitor)  ○ # EU: Retinopathy of prematurity

Submission in preparation
Aflibercept 8MG  ○ # Diabetic Macular Edema (DME) (PHOTON ⁴) # Neovasc. Age-rel. Macular Degen. (nAMD) (PULSAR)

- Oncology
- Cardiovascular Diseases
- Women's Health
- Others

- New therapeutic entity
- Life cycle management

-  Antibody
-  Biologic
-  Cell Therapy
-  Contrast Agent
-  Gene Therapy
-  Radiotherapy
-  Small Molecule

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND ³ Conducted by Merck & Co ⁴ Conducted by Regeneron Pharmaceuticals